Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=90 Randomized Double-blind Prevention

Transversus Abdominis Plane (TAP) Block for Cesarean Section

Hyperalgesia, Secondary

Bottom Line

View on ClinicalTrials.gov: NCT01015807 ↗
Enrolled (actual)
90
Serious AEs
0.0%
Results posted
May 2017
Primary outcome: Primary: Wound Hyperalgesia Index (WHA) Assessed 48 Hrs After Block Placement in the Different Groups — 1.07; 1.27; 0.74 cm^2 — p=0.48

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bupivacaine Placebo (Drug); Clonidine Placebo (Drug); Bupivacaine (Drug); Clonidine (Drug)
Age
Adult · 18+ yrs
Sex
Female
Sponsor
University of Washington
Primary completion
Aug 2010

Outcome Measures

OutcomeResultp-value
PRIMARY
Wound Hyperalgesia Index (WHA) Assessed 48 Hrs After Block Placement in the Different Groups		 1.07; 1.27; 0.74 0.48

Summary

The purpose of this study is to determine whether a transversus abdominis plane (TAP) block with Clonidine added to the injectate (Clo-TAP) performed approximately 2hrs after the cesarean section (CS) will decrease the amount of postoperative hyperalgesia and ultimately reduce post-CS chronic pain.

Eligibility Criteria

Inclusion Criteria

  • non-laboring women who will benefit from and have clinically consented to a scheduled or non-scheduled cesarean delivery under spinal anesthesia
  • English speaking (UW Site) or Portuguese speaking (Brazil site)
  • aged between 18 and 45 years
  • BMI < 40
  • ASA physical status class I or II

Exclusion Criteria

  • laboring women undergoing a non-scheduled cesarean delivery
  • non-English speaking (UW Site) or non-Portuguese speaking (Brazil site)
  • previous spinal surgery
  • contraindications for neuraxial anesthesia
  • allergy to local anesthetic, ultrasound conduction gel, or Clonidine
  • history of chronic pain
  • inability to receive intraoperative Toradol
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01015807). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search